免疫检查点抑制剂治疗相关眼部不良反应的研究进展  

Research progress on the ocular adverse effects associated with immune checkpoint inhibitor therapy

作　　者：郭未艳 蔺雪梅 吴松笛 Guo Weiyan;Lin Xuemei;Wu Songdi(Department of Neuro-ophthalmology,The First Affiliated Hospital of Northwest University(Xi'anNo.1 Hospital),Xi'an 710002,China;Department of Pharmacy,The First Affiliated Hospital of Northwest University(Xi'an No.1 Hospital),Xi'an 710002,China;Xi'an Key Laboratory of Innovation and Transformation of Neuroimmunological Diseases,Xi'an 710002,China)

机构地区：[1]西北大学附属第一医院(西安市第一医院)神经眼科,西安710002 [2]西北大学附属第一医院(西安市第一医院)药剂科,西安710002 [3]西安市神经免疫疾病创新转化重点实验室,西安710002

出　　处：《中华眼底病杂志》2023年第12期1033-1038,共6页Chinese Journal of Ocular Fundus Diseases

基　　金：陕西省中医药管理局项目(2022-SLRH-LJ-013);陕西省科技计划项目(2022SF-381、2023-YBSF-048);西安市卫生健康委项目(2023qn04)。

摘　　要：免疫检查点抑制剂(ICI)通过调节免疫细胞与癌细胞的相互作用,促进免疫系统去抑制作用,从而靶向多种类型的恶性肿瘤,为肿瘤学领域带来了革命性变化。然而免疫系统的调节也会引发相关的不良反应。ICI相关的眼部不良反应发病率低,如不及时诊治会对患者产生严重影响。但治疗目前尚无相关临床治疗指南,治疗决策很大程度上取决于临床判断和经验。ICI相关的眼部不良反应的发病机制目前尚不完全明确,对其作用机制的进一步研究能够为ICI相关的眼部不良反应的早期诊断和治疗提供新思路。Immune checkpoint inhibitors(ICI)have revolutionized the field of oncology by regulating the interaction between immune cells and cancer cells and promoting the disinhibition of the immune system,thus targeting various types of malignant tumors.However,the regulation of the immune system can also trigger related adverse reactions.Currently,there are no specific clinical guidelines for the treatment of these adverse reactions.Treatment decisions largely depend on clinical judgment and experience.The pathogenesis of ICIrelated ocular adverse events is not fully understood at present.Further research on the specific mechanisms of action can provide new insights into the early diagnosis and treatment of ICI-related ocular adverse events.

关 键 词：免疫检查点抑制剂 眼部不良反应 综述 

分 类 号：R771.3[医药卫生—眼科]